Search Articles
Citing misrepresentations about declining revenues and flatlining sales of the Panorama product, a class says shares of Natera have plummeted since the leading genetic-testing company went public 18 months ago.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.